Labcorp (NYSE: LH), a leading global life sciences company, is partnering with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening. To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference of National…
HCA Healthcare, Inc. (NYSE: HCA) today announced that its wholly owned subsidiary, HCA Inc., proposes to offer senior notes, subject to market and other considerations. Actual terms of the senior notes, including maturity, interest rate and principal amount, will depend…
HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced its fourth annual month-long community volunteer campaign, Community Days: A Month of Service. During the month of April, HCA Healthcare is providing volunteer time and financial contributions to…
HCA Healthcare, Inc. (NYSE:HCA), today announced financial and operating results for the first quarter ended March 31, 2023. Key first quarter metrics (all percentage changes compare 1Q 2023 to 1Q 2022 unless otherwise noted): “Once again this quarter, our colleagues demonstrated a…
HCA Healthcare, Inc. (NYSE: HCA) today announced Jyric Sims, Ph.D., will become president of the company’s West Florida Division, effective June 12. Jyric Sims, Ph.D. (Photo: Business Wire) Sims, who currently is CEO of HCA Healthcare’s Medical City Plano and Medical…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, is scheduled to participate in a fireside chat at the Bank of America Securities 2023…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC), by a vote of 11 to 1 with one abstention, supported FDA…
RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2023. “Inspired by our commitment to bring bold science forward to address critical unmet patient needs, we…
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the first-line…
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy,…